B-cell maturation agent (BCMA), which is expressed on the surface of virtually all myeloma cells, has been called “the perfect target” by Dr. Nikhil Munshi, president of the International Myeloma Society. Additional therapies are being developed for novel targets in addition to BCMA include antibody drug conjugates (ADCs), CAR T, bispecific T-cell engagers (BiTEs or bispecifics), and new immunotherapies in research like trispecifics.
Ide-cel was approved on March 26, the ADC Blenrep ® was approved last year, and a number of bispecifics clinical trials are currently being conducted. Initial approval of these therapies will be focused on patients who relapse of refractory to multiple lines of treatment, but experts are increasingly optimistic that they will be used earlier with more experience.
This program will be a deep dive into why these targets are important, how their mechanisms function, and how they are being integrated into myeloma therapy.
Please join us on Saturday, April 10 for a 75 minute program, beginning at 12:00 pm Eastern Standard Time (9 am Pacific, 10 am Mountain, 11 am Central, 17:00 GMT, 18:00 CET). Our speakers will be:
<a href="https://healthtree.org/aml/community">Find more myeloma news and information on www.myelomacrowd.org</a>
Copyright © 2021 HealthTree Foundation. All Rights Reserved.
The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811